Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 10/20 | 0.58 |
| ▸ | FLT3 | P36888 | 3/20 | 0.49 |
| ▸ | KDR | P35968 | 6/20 | 0.47 |
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.47 |
| ▸ | FLT1 | P17948 | 4/20 | 0.47 |
| ▸ | FLT4 | P35916 | 4/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371889 | 0.89 | MET (0.60) | METFLT3KDREGFRFGFR1 | |
| SCHEMBL372055 | 0.88 | MET (0.47) | METFLT3KDRPDGFRA | |
| SCHEMBL14315645 | 0.88 | KRAS (0.47) | METKDRPDGFRA | |
| SCHEMBL10254472 | 0.87 | FLT3 (0.49) | METFLT3KDRPDGFRA | |
| SCHEMBL3542937 | 0.86 | MET (0.56) | METFLT3KDREGFRPDGFRA | |
| SCHEMBL3542938 | 0.86 | MET (0.56) | METFLT3KDREGFRPDGFRA | |
| SCHEMBL15338410 | 0.86 | EGFR (0.63) | METFLT3KDREGFRFGFR1 | |
| SCHEMBL371890 | 0.86 | MET (0.46) | METFLT3KDRPDGFRA | |
| SCHEMBL29487188 | 0.85 | PDGFRA (0.59) | METKDRPDGFRA | |
| SCHEMBL174159 | 0.85 | PDGFRA (0.59) | METKDRPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008035209-A2 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-27 | — | — | WO | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | MET 3/4885FLT3 10/4885KDR 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.